Eli Lilly (LLY) Asset Writedowns and Impairment (2011 - 2012)
Eli Lilly posted quarterly Asset Writedowns and Impairment of $221.0 million for Q4 2012, down 26.94% year-on-year from $302.5 million in Q1 2012, and down 26.94% on a QoQ basis from $302.5 million in Q4 2011.
Eli Lilly (LLY) has 2 years of Asset Writedowns and Impairment data on file, last reported at $221.0 million in Q4 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 221.00 Mn |
| Dec 31, 2012 | 221.00 Mn |
| Dec 31, 2011 | 302.50 Mn |
| Dec 31, 2011 | 302.50 Mn |